Efinaconazole

DB09040ApprovedInvestigationalSmall moleculeAntifungal AgentsAzole Antifungals

Efinaconazole is an antifungal agent used to treat onychomycosis, a fungal infection of the nail. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

Chemical structure of Efinaconazole
Mechanism
Curator reviewed
Primary indication
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.Curator reviewed · 1 structured indication
Formula / weight
C18H22F2N4O · 348.398 g/mol (avg)
First approval
Canada, 2020 · United States, 2014
Code names
IDP-108 · KP-103
Brand names
  • Jublia

Resolves to

Compound
UNIIJ82SB7FXWBCAS164650-44-6ChEMBLCHEMBL2103877ChEBI82718PubChem489181KEGGD10021
Clinical / RWD
RxNorm1539753ATCD01AC19
Structure
InChIKeyNFEZZTICAUWDHU-RDTXWAMCSA-NSMILESC[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Targets
P10613ERG11

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2Marketed productsAcross 2 countries and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Efinaconazole, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In